NDA 50-573/S-017; NDA 50-574/S-026; NDA 50-625/S-028;
NDA 50-715/S-008; NDA 50-716/S-012 **DEC 21 1999**

Novartis Pharmaceuticals Corporation
Attention: Ronald G. Van Valen
Associate Director, Drug Regulatory Affairs
59 Route 10
East Hanover, New Jersey 07936

Dear Mr. Van Valen:

Please refer to your supplemental new drug applications dated December 1, 1999, received December 2, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Sandimmune® (cyclosporine injection, USP) Injection, 50 mg/mL, Sandimmune (cyclosporine oral solution, USP) Oral Solution, 100 mg/mL, Sandimmune® (cyclosporine capsules, USP) Soft Gelatin Capsules, 25 mg, 50 mg, 100 mg, Neoral® Soft Gelatin Capsules (cyclosporine capsules, USP) MODIFIED, 25 mg, 100 mg, and Neoral® Oral Solution (cyclosporine oral solution, USP) MODIFIED, 100 mg/mL.

These supplemental new drug applications provide for a change to the established names of Neoral® as they appear in the labeling of these products. Specifically, each instance of "(cyclosporine capsules for microemulsion)" has been replaced with "(cyclosporine capsules, USP) MODIFIED" and each instance of "(cyclosporine oral solution for microemulsion)" has been replaced with "(cyclosporine oral solution. USP) MODIFIED." In the first sentence of the Clinical Trials/Rheumatoid Arthritis section of the Neoral® package insert, "Sandimmune® (cyclosporine)" has been replaced with "Sandimmune®" and "Neoral® (cyclosporine for microemulsion)" has been replaced with "Neoral®."

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter, and those changes are to be implemented fully no later than 30 days from the date of this letter.

We note that the text of the package insert also includes new information about neurotoxicity that was added to the labeling under supplements submitted pursuant to 21 CFR 3 14.70(c) - "Supplements for changes that may be made before FDA approval." [Please refer to NDA 50-574/S-025 NDA 50-625/S-027. NDA 50-715/S-007 and NDA 50-716/S-011 submitted September 24, 1999, received September 29, 1999 and NDA 50- 573/S-0l8 submitted December 10, 1999, received December 13, 1999.] We have not completed review of the information submitted in support of this addition to the labeling and, therefore, this approval letter does not constitute action on these supplements. Action on these supplements will be taken at a later date.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert and immediate container and carton labels submitted December 1, 1999).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed to each application. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 50-573/S-017, 50-574/S-S-026, 50-625/S-028. 50-715/S-008, 50-716/S-012." Approval of these submissions by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e.. a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MED WATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions. contact Robin Anderson, Regulatory Review Officer, at (301) 827-2127.

Sincerely,

Mark J. Goldberger, M.D., M.P.H.
Director
Division of Special Pathogen and Immunologic
Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research